<DOC>
	<DOC>NCT00651911</DOC>
	<brief_summary>An open-label study to determine the efficacy and safety of Rasburicase used for the prevention and treatment of tumor lysis syndrome</brief_summary>
	<brief_title>Fasturtec TLS Treatment / Prophylysis</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Tumor Lysis Syndrome</mesh_term>
	<mesh_term>Rasburicase</mesh_term>
	<criteria>Chemotherapy planned for at least 3 cycles Undergoing cytoreductive chemotherapy for ALL, multiple myeloma or Burkitt's lymphoma stage III or IV With a minimum life expectancy of 3 months Uric acid &gt; 8 mg% Negative pregnancy test &lt; or =to 2 weeks and efficient contraceptive method. Negative HIV serology &lt; or =to 4 weeks Patient or legal guardian has signed a written informed consent Hypersensitivity to uricases or any of the excipients Known history of G6PD deficiency. Previous treatment with Rasburicase or UricozymeÂ® Pregnancy or lactation Treatment with any investigational drug within 30 days before planned first Rasburicase administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>